Glycaemic Biomarkers and Biological Age

Key Takeaways

Fasting glucose is included in Phenotypic Age, but there it contributes to a multi-system mortality model rather than measuring ageing directly. [1]
HbA1c reflects glycaemic exposure over a longer interval than a single glucose sample, while oral-glucose tests and continuous monitoring reveal dynamic patterns that fasting measurements can miss. [2] [3] [4]
Age-related differences in glucose regulation involve insulin action, insulin secretion, body composition, and illness; chronological age is therefore not the only explanation for an adverse result. [5]
No glycaemic marker is a standalone biological-age clock, and associations with mortality or frailty vary across populations and clinical contexts. [6] [7]

Glycaemic biomarkers describe how glucose is present, processed, and regulated over different time scales. They are relevant to ageing research because glucose regulation is connected with metabolic reserve and later health outcomes, and because fasting glucose is one component of the widely used Phenotypic Age model. These roles make glycaemic measures informative contributors to biological-age research, but not direct measurements of the ageing process itself. [1] [6]

Who This Is Useful For

This page is useful for readers interpreting glucose or HbA1c in a biological-age panel, comparing a fasting test with an oral-glucose test or continuous glucose monitor, or assessing claims that stable glucose alone demonstrates slower ageing. The evidence is most useful when these measurements are treated as complementary views of metabolic physiology. [2] [3] [4]

Common Glycaemic Measures

Measure	What It Captures	Research Value	Main Limitation
Fasting glucose	Glucose concentration at one fasting time point	Available in large cohorts and included in Phenotypic Age [1]	Varies with body composition, medication, and disease context [9]
HbA1c	Glycation of haemoglobin during the circulating life of red blood cells	Summarizes longer-term glycaemic exposure without requiring fasting [2]	Can shift with age and red-cell turnover independently of glucose [2]
Oral glucose tolerance test	Glucose and sometimes insulin response after a standardized glucose load	Reveals post-load regulation that fasting values can miss [3]	Requires a standardized glucose load and timed sampling [3]
Insulin-based indices	Proxies for insulin resistance, sensitivity, or secretion	Helps separate glucose concentration from its regulatory mechanisms [5]	Results depend on the model, adiposity, and sampling design [5]
Continuous glucose monitoring	Repeated interstitial-glucose estimates, including mean level and variability	Describes free-living patterns across meals, activity, and sleep [4]	Age-specific reference evidence and outcome validation remain limited [8]

Why Glucose Regulation Changes Across Age

Comparisons of younger and older adults have found lower insulin action and impaired insulin secretion relative to insulin resistance in older groups. In one mechanistic study, differences in adiposity and visceral fat accounted for the age-group difference in insulin action, while beta-cell function remained reduced when evaluated relative to insulin resistance. This separates age-associated physiology from a simple claim that age itself inevitably raises glucose. [5]

Dynamic testing can expose differences that fasting measurements conceal. Among very old women without known diabetes, frailty groups had similar fasting glucose and insulin-resistance estimates, whereas frail participants had higher glucose after an oral challenge. The result was cross-sectional and from a small sample, but it illustrates why fasting and post-load markers are not interchangeable. [3]

Fasting Glucose in Biological-Age Models

Phenotypic Age combines chronological age with nine clinical biomarkers selected through mortality-risk modelling; glucose is one of those biomarkers. A higher glucose contribution can therefore increase the modelled age estimate, but the calculation does not establish that glucose is a master mechanism or quantify the age of a particular organ. [1]

Outcome associations are also non-linear and context-dependent. A cohort of more than 15 million Korean adults found a J-shaped association between fasting glucose and all-cause mortality across body-mass categories, with substantial interaction among glucose, body mass, sex, and age. Such results caution against translating a single concentration into a universal biological-age increment. [9]

HbA1c: Longer-Term Signal, Different Sources of Bias

HbA1c records glucose exposure through haemoglobin glycation and is less dependent on the conditions of one fasting morning. Population data from two German cohorts found that HbA1c increased with age even in carefully selected people without diabetes, while the authors also noted that age-associated changes in red-cell production or clearance can affect the measure. [2]

Prognostic results are mixed. In NHANES participants aged 65 years or older, high HbA1c was associated with greater mortality among people with diagnosed or undiagnosed diabetes. By contrast, a Cardiovascular Health Study analysis of older adults without diabetes did not find a statistically significant association between baseline HbA1c and all-cause or cardiovascular mortality. [6] [7]

Continuous Monitoring and Glycaemic Variability

Continuous glucose monitoring adds mean glucose, time in specified ranges, and within-day variability. In a prospective study of 153 healthy participants, mean sensor glucose was similar across most age groups but modestly higher among participants older than 60 years. The small older subgroup and short monitoring period limit what can be inferred about ageing trajectories. [4]

Larger observational datasets in people without diabetes show that CGM metrics correlate with HbA1c, insulin-resistance estimates, predicted cardiovascular risk, diet, and daily habits. These associations make CGM useful for phenotyping current metabolic state, while also showing why variability is not a specific readout of biological ageing. [10]

Evidence Quality and Interpretation

Confidence is strong that glycaemic markers capture distinct time scales and that fasting glucose is an established component of Phenotypic Age. Confidence is also strong that HbA1c and fasting glucose are not interchangeable and that dynamic tests can reveal information absent from fasting samples. [1] [2] [3]

Confidence is moderate that adverse glycaemic patterns track frailty, mortality, or other age-related outcomes, because most relevant evidence is observational and results vary by diabetes status, body composition, age, and marker. [3] [6] [7] [9]

Confidence is weaker for treating CGM variability or any isolated glycaemic value as a validated measure of whole-body biological age. Existing studies often describe cross-sectional physiology over days rather than prospective, multisystem ageing over years. [4] [8] [10]

What This Does Not Mean

It does not mean a normal fasting glucose establishes a younger biological age; post-load regulation and other physiological systems may differ. [1] [3]
It does not mean a higher HbA1c always represents greater glycaemic exposure, because red-cell biology can alter HbA1c independently. [2]
It does not mean glucose variability measured over a few days is a validated clock of long-term ageing. [4] [8]
It does not mean observational associations identify whether dysglycaemia causes accelerated ageing, results from disease burden, or shares upstream determinants with both. [6] [9]

Practical Interpretation Examples

If fasting glucose raises a Phenotypic Age estimate: it is contributing statistical mortality information inside a multi-biomarker model, not independently dating the body. [1]
If HbA1c and fasting glucose disagree: they reflect different time windows, and red-cell turnover or post-meal glucose patterns may contribute to the difference. [2] [3]
If a CGM shows greater variability: this describes short-term glucose dynamics, but interpretation requires meal, activity, sleep, sensor, and metabolic context. [8] [10]

Summary

Glycaemic biomarkers contribute useful information about metabolic regulation and risk, but they do so across different time scales and with different confounders. Fasting glucose has an established place in a major composite biological-age model; HbA1c, oral-glucose responses, insulin indices, and CGM metrics add complementary information. Their strongest interpretation is as components of a wider physiological profile, not standalone estimates of whole-body biological age. [1] [2] [5]

References

Levine, M. E., Lu, A. T., Quach, A., Chen, B. H., Assimes, T. L., Bandinelli, S., et al. (2018). An epigenetic biomarker of aging for lifespan and healthspan. Aging. https://pmc.ncbi.nlm.nih.gov/articles/PMC5940111/
Masuch, A., Friedrich, N., Roth, J., Nauck, M., Müller, U. A., & Petersmann, A. (2019). Preventing misdiagnosis of diabetes in the elderly: age-dependent HbA1c reference intervals derived from two population-based study cohorts. BMC Endocrine Disorders. https://pmc.ncbi.nlm.nih.gov/articles/PMC6371438/
Kalyani, R. R., Varadhan, R., Weiss, C. O., Fried, L. P., & Cappola, A. R. (2012). Frailty status and altered glucose-insulin dynamics. Journal of Gerontology: Medical Sciences. https://pubmed.ncbi.nlm.nih.gov/21873592/
Shah, V. N., DuBose, S. N., Li, Z., Beck, R. W., Peters, A. L., Weinstock, R. S., et al. (2019). Continuous glucose monitoring profiles in healthy nondiabetic participants: a multicenter prospective study. Journal of Clinical Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/31127824/
Basu, R., Breda, E., Oberg, A. L., Powell, C. C., Dalla Man, C., Basu, A., et al. (2003). Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. Diabetes. https://pubmed.ncbi.nlm.nih.gov/12829641/
Palta, P., Huang, E. S., Kalyani, R. R., Golden, S. H., & Yeh, H. C. (2017). Hemoglobin A1c and mortality in older adults with and without diabetes: results from the National Health and Nutrition Examination Surveys (1988–2011). Diabetes Care. https://pubmed.ncbi.nlm.nih.gov/28223299/
Chonchol, M., Katz, R., Fried, L. F., Sarnak, M. J., Siscovick, D. S., Newman, A. B., et al. (2010). Glycosylated hemoglobin and the risk of death and cardiovascular mortality in the elderly. Nutrition, Metabolism and Cardiovascular Diseases. https://pubmed.ncbi.nlm.nih.gov/19364638/
Daya, N. R., Fang, M., Wang, D., Valint, A., Windham, B. G., Coresh, J., et al. (2025). Glucose abnormalities detected by continuous glucose monitoring in very old adults with and without diabetes. Diabetes Care. https://pubmed.ncbi.nlm.nih.gov/39705138/
Jung, M. H., Yi, S. W., An, S. J., Balkau, B., Yi, J. J., & Kim, H. (2020). Complex interaction of fasting glucose, body mass index, age and sex on all-cause mortality: a cohort study in 15 million Korean adults. Diabetologia. https://pubmed.ncbi.nlm.nih.gov/32424541/
Bermingham, K. M., Smith, H. A., Duncan, E. L., Gonzalez, J. T., Valdes, A. M., Franks, P. W., et al. (2026). Associations of continuous glucose monitor derived time in range and glycaemic variability with diet, lifestyle and demographics. Nature Communications. https://pmc.ncbi.nlm.nih.gov/articles/PMC13187318/

Educational Disclaimer

This content is provided for educational purposes only and does not constitute medical advice.